

# QC net in hospitals POCT



Marija Prezelj

Institute of Clinical Chemistry and Biochemistry University Medical Centre Ljubljana, Slovenia

# University Medical Centre Ljubljana

- 2 179 Patient beds
  101 631 In-patient admissions
  761 824 Out-patient visits
  5,59 days Average length of stay
- 7 713 Employees1 197 Physicians and dentists
- 3 693 Nurses, midwives

- 5,113.527 Number of lab. test (Institute for Clinical Chemistry and Biochemistry)



2004

# Legislation, Standards, Guideline, Regulatory requirements

#### By-law

 Pravilnik o pogojih, ki jih morajo izpolnjevati laboratoriji za izvajanje preiskav na področju laboratorijske medicine (Ur.list RS 64/2004)

#### Standards, Guidelines





ISO 15189 Medical laboratories — Requirements for quality and competence
 ISO 22870: 2006 Point-of-care testing - Requirements for quality and competence
 CLSI POCT Guidelines (> 12)

#### 2005 - 2006



- Institute for Clinical Chemistry and Biochemistry organized seminar for nurses, midwives and technitian in UMC Ljubljana
  - Guidelines How to perform Point-of Care Testing



- Institute for Clinical Chemistry and Biochemistry & Nurses and Midwives Association of Slovenia
  - Seminar with hands on workshop: Guidelines How to perform Point-of Care Testing

2007

#### Project at the tertiary level UMC Ljubljana

- Creating qaulity improvement opportunities for point-of-care testing in UMC Ljubljana
- Implementation and management of a safe and effective POCT service within the hospital environment.
  - Number of POCT devices
  - Interdisciplinary committee for POCT in UMCL
  - Organizing sheme of POCT responsibility
  - Quality assurance audit at all sites
  - External Quality Assessment Sheme in UMCL
  - Connecivity to LIS

#### 2008 (12.5.2008)

#### Governance of UMC Ljubljana

#### Interdisciplinary committee for POCT in UMCL

- Central role of Institute of Clinical Chemistry and Biochemistry
- Institue of Clinical Chemistry and Biochemistry is responsible for the quality assurance programme.
- A quality assurance audit was set up to audit all sites that perform POC testing.
- The committee is responsible for the selection and procurement of the most POCT equipment
- The group is responsible for implementation, monitoring of processrelated protocols
- Internal quality control and participation in external quality assessment scheme
- POCT co-ordinator responsibility
- determining budgetary responsibility for individual POCT services

#### 2008 (15. may 2008) Situation in UMC Ljubljana

#### LIST of POCT devices


- Glucose meters 139
- Blood gas analysers
   25
- Hemoglobin meters16
- Coagulation meter 10
- **Troponin** 10
- Urinalysis (including analysers)
- ???
- ??
- •?

- GLUCOSE METERS
  - ABBOTT
  - HEMOCUE
  - **ROCHE**
  - BAYER
  - □ J&J
  - ???
- GAS ANALISYS
  - ABBOTT
  - RADIOMETER
  - ROCHE
  - ??


Number of tests (glucose, urea and creatinine) in Institute of Clinical Chemistry and Biochemistry


#### Glucose reagent slide

2010	379 300 €
2011	390 235 €




## External Quality Control Results






ABBOT BAYER HEMOCUELIFESCAN ROCHE

Ν	mediana	CV	SD
15	6.29	4.47	0.281
75	5.29	5.32	0.315
58	5.49	3.93	0.216
50	4.77	2.22	0.106
16	7.78	6.66	0.518
223			



Standard deviation



# Barcode identification label for POCT

#### For users

# WERKLY

# For patient ID









Bar code printer, Bar code reader....


Barcode printers 91 (150)Barcode readers








#### Hospital Information Systems in UMC Ljubljana



Connectivity System Components Point Point – of Care Connectivity (POCT 01-A2) (CLSI Clinical and Laboratory Standards Institute)



# Connection Systems in UMC Ljubljana

- i-STAT System (Abbott)
- IT 1000 (Roche)
- Direct Connection to LIS

## Blood gases

## i-STAT System (Abbott)

- Division of Neurology
  - Neurological Emergency Unit
  - Department of Vascular Neurology and Intensive Therapy
- Division of Surgery
  - Department of Anaesthetics and Surgical Intensive Care
- Division of Paediatrics
  - Unit of Pulmonary Diseases

#### Radiometer (direct connection to LIS)

- Division of Surgery
  - Department of Paediatrics Surgery and Intensive Care
  - Department of Anaesthetics and Surgical Intensive Care
- Department of Infectious Diseases and Febrile Illnesses

#### Glucose


- Accu-Chek Inform II System (IT-1000 Roche)
  - Division of Internal Medicine, Department of Intensive Medicine
  - Department of Infectious Diseases and Febrile Illne

#### Coagulometer

- i-STAT System (Abbott)
  - Division of Neurology
    - Neurological Emergency Unit
    - Department of Vascular Neurology and Intensive Therapy
  - Division of Surgery
    - Department of Anaesthetics and Surgical Intensive Care
  - Division of Paediatrics
    - Unit of Pulmonary Diseases







# Quality control results

Lot Number	Operator ID	Date - Time	Location	Department	Comment	Interface Comment	Order Number	Serial Number	Panel	Sent	Resu
12310	6	14.9.2013 09:46:	Nevro urgenca	Unassigned				327906	CG8+	No	
45482131	2	7.9.2013 08:30:3	Nevro urgenca	Unassigned				327906	PT	No	
42575131	1	6.9.2013 15:00:0	Nevro urgenca	Unassigned				327906	EC8+	No	
41987131	5	31.8.2013 07:56:	Nevro urgenca	Unassigned				327906	CG8+	No	
45482131	5	31.8.2013 07:44:	Nevro urgenca	Unassigned				327906	PT	No	
41987131	6	23.8.2013 16:43:	Nevro urgenca	Unassigned				327906	CG8+	No	
111038	3	17.8.2013 08:03:	Nevro urgenca	Unassigned				327906	CG8+	No	
	12	10.8.2013 08:20:	Nevro urgenca	Unassigned				327906	PT	No	
41987123	12	10.8.2013 08:09:	Nevro urgenca	Unassigned				327906	CG8+	No	
45482130	5	3.8.2013 07:41:0	Nevro urgenca	Unassigned				327906	PT	No	
41987123	5	2.8.2013 18:11:1	Nevro urgenca	Unassigned				327906	CG8+	No	
42572131	5	2.8.2013 18:05:3	Nevro urgenca	Unassigned				327906	EC8+	No	
	14	27.7.2013 11:05:	-	-					CG8+	No	
	14	27.7.2013 10:56:	Nevro urgenca	Unassigned				327906	PT	No	
	9	20.7.2013 08:15:	Nevro urgenca	Unassigned				327906	PT	No	
06F1301	9	20.7.2013 08:01:	Nevro urgenca	Unassigned				327906	CG8+	No	
281032	12	12.7.2013 16:30:	Nevro urgenca	Unassigned				327906	PT	No	
04J5021	12	12.7.2013 16:24:	Nevro urgenca	Unassigned				327906	PT	No	
<											
Method:	i-STAT		•			ewer last up: I results in vi		·	311:43		

a x

# Quality control results

Site Name: Date - Time:	Klinični cent 14.9.2013 09		a Location: Nevro urgenca	Result Typ	e: Control Result	
ot Number: Operator ID: Oepartment: Order Number Interface Com Comment:	-			Original Operator II Serial Number: Panel:	D: 6 327906 CG8+ Sent: No	
	Te pH (37C) pc02 (37C) P02 (37C) HC03 BE s02 Glu Na K TC02 iCa Hct Hb	est Results 6.561 12.02 kP 8.1 mr <.30 mr <.30 mr 84 % 1.5 mr 100 mr 2.1 mr 2.1 mr 2.1 mr 2.25 mr <10 %l <> gA	a a hol/L hol/L hol/L hol/L hol/L hol/L hol/L hol/L	Cartridge Lot Control Lot Level Panel Code Battery Vottage Preferences Name Software Uses Star-out Code Fluid Code i-STAT ID Instrument Temp. Pressure Preferences Revision Test Inst. Qualified Operator Instrument QC Due Inst. Qualified Reagent	Extra Data: 419///131110238 12310 0 05 7,70/ 13705EFK JAMS135C-A26 7174 00 80 13 25,2C 738,4 mmHg 10 2 YES NO YES	

							annianna.	•
					CLEW:		cinecann	90)
					C38+, E97+, E96+	, G3+,Cres & CG4+	LOT	K.L. N. U. Wor Y
							8 (Mean)	Zelbereich gemäß RillBÄK 2008
					Na	mmol/L,mEq/L	121	117 - 125
					ĸ	mmol/L,mEq/L	2,9	2,8 - 3,0
					/Ce	rmo/L	1,43	1,32 - 1,54
						mgdL	5,7	5,3 - 6,1
32	CLEW A26 734388-01 B.pdf - F	Foxit Reader - [L1 Control 101032	CLEW A26 734388-01 B.pdf	0 _ 8 ×		mEqL	2,9	2,7 - 3,1
	ools Comments Forms Help				PH		7,026	6,998 - 7,054
			- 4 0		PCO2	mm/Hg	57,6	53,9 - 61,3
	🔳 🖳 🕎 🛃 🔓 📄	🔟 🗟 * 🔏 🖁 💾	🖂 🍋 🛃			kPa	7,68	7,18 - 8,18
032_C	L 🛞			Fast mobile PDF reader on iPad	PO2	rm/Hg	91	85 - 97
_					Glucose/G ti	kPa	12,1	11,3 - 12,9 37 - 47
				<u>^</u>	Giucose/Giu	mg/dL		
						git mmol/L	0,42	0,37 - 0,47 2,1 - 2,7
	i-STAT <sup>®</sup> Level 1	Control			Orestinge/Cree		2,4	2,1-2,7
	LOT 101032				CheldhinerCred	mgdL umol/L	345	3,5 - 4,3
		00			Lectate/Lec	mmoi/L	7.80	6.94 - 8.66
	Exp.: 2013	-00				mgdL	70.3	62.6 - 78.0
	CLEW: A26/C	00				gL	0.703	0.626 - 0.780
	OLLII. ALU/O	20						
	CG8+. EG7+. EG6+. G	3+. Crea & CG4+ LOT	K.I. N.U.Wo	rY =	Crea		LOT	A
	CG8+, EG7+, EG6+, G	5		R (Range)	Crea		LOT X (Mean)	A Zelbereich gemäß RillBÄK 2008
	Na		<b>(Mean)</b> 121	R (Range) 117-126		madi	X (Mean)	Zelbereich gemäß RilBÄK 2008
		5	z (Mean)	R (Range)	Orea Oreatinhe/Cree	mgdL unol/L		Zelbereich gemäß RillBÄK 2008 3,5 - 4,5
	Na	mmol/L, mEq/L	<b>(Mean)</b> 121	R (Range) 117-126		mgdL unol/L	X (Mean) 4,0	Zelbereich gemäß RilBÄK 2008
	Na K	mmol/L, mEq/L mmol/L, mEq/L mmol/L	x (Mean) 121 2.9 1.43	R (Range) 117-126 2.6-3.2 1.33-1.54	Oreatinhe/Cree	unoilL	X (Mean) 4,0	Zelbereich gemäß RillBÄK 2008 3,5 - 4,5
	Na K	mmol/L, mEq/L mmol/L, mEq/L mmol/L mmol/L mg/dL	(Mean) 121 2.9 1.43 5.7	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2		unoilL	X (Mean) 4,0	Zelbereich gemäß RiilBAK 2008 3,5 - 4,5 313 - 395 F, Q, H J or K
	Na K	mmol/L, mEq/L mmol/L, mEq/L mmol/L	x (Mean) 121 2.9 1.43	R (Range) 117-126 2.6-3.2 1.33-1.54	Oreatinhe/Cree	unoilL	8 (Mean) 4,0 354	Zielbereich gemäß RIIBAX 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß
	Na K iCa	s mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L	<b>x</b> (Mean) 121 2.9 1.43 5.7 2.9	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087	Creatinhe/Crea EC8+, 6+, EC4+, E3	uno/L	X (Mean) 4,0 354 LOT X (Mean)	Zielbereich gemäß RIIBAX 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß RIIBAX 2008
	Na K iCa	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg	x (Mean) 121 2.9 1.43 5.7 2.9 7.037 58.7	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2	Creatinha/Crea E03+, 6+, E04+, E3 Na	unol/L + & G mmol/L,mEq/L	X (Mean) 4,0 354 LOT X (Mean) 120	Zielbereich gemäß RiHBAX 2008 3,5 - 4,5 313 - 395 F, G, H J or K Zielbereich gemäß RiHBAX 2008 116 - 124
	Na K iCa pH <b>P</b> CO <sub>2</sub>	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa	R (Mean) 121 2.9 1.43 5.7 2.9 7.037 58.7 7.82	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82	Creatinhe/Crea EC3+, 6+, EC4+, E3 Na K	unol/L + & G mmol/L,mEq/L mmol/L,mEq/L	X (Mean) 4,0 354 LOT X (Mean) 120 2,8	Zielbereich gemäß RillBAK 2008 3,5 - 4,5 313 - 395 F. G. H.J. or K Zielbereich gemäß RillBAK 2008 116 - 124 2,7 - 2,9
	Na K iCa	s mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa mm Hg	R (Mean) 121 2.9 1.43 5.7 2.9 7.037 58.7 7.82 90	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105	Ovatinha/Crea E03+, 6+, E04+, E3 Na K O	unol/L + & G mmol/L,mEq/L	X (Mean) 4,0 354 Lot X (Mean) 120 2,8 79	Zielbereich gemäß RillBAX 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß RillBAX 2008 116 - 124 2,7 - 2,9 75 - 83
	Na K iCa pH PCO <sub>2</sub> PO <sub>2</sub>	s mmol/L, mEq/L mmol/L, mEq/L mg/dL mg/dL mEq/L mm Hg kPa mm Hg kPa	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0	Osatinha/Crea E03+, 6+, E04+, E3 Na K C pH	unol/L + & G mmol/L,mEq/L mmol/L,mEq/L mmol/L, mEq/L	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,959	Zielbereich gemäß RIIBAX 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß RIIBAX 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017
	Na K iCa pH <b>P</b> CO <sub>2</sub>	s mmol/L, mEq/L mmol/L, mEq/L mg/dL mEq/L mEq/L kPa mm Hg kPa mm Hg kPa mg/dL	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         42	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0 33-51	Ovatinha/Crea E03+, 6+, E04+, E3 Na K O	unoilL + & G mmoilL,mEq/L mmoilL,mEq/L mmoilL, mEq/L mm/Hg	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,980 68,1	Zielbereich gemäß RittBAK 2008 3,5 - 4,5 313 - 395 F, G, H J or K Zielbereich gemäß RittBAK 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 63,7 - 72,5
	Na K iCa pH PCO <sub>2</sub> PO <sub>2</sub>	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa mm Hg kPa mm Hg g/L	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0 33-51 0.33-0.51	Osatinha/Crea E03+, 6+, E04+, E3 Na K C D PH P CO <sub>2</sub>	unoilL + & G mmoilL,mEq/L mmoilL,mEq/L mmoilL, mEq/L kPa	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,989 68,1 9,08	Zielbereich gemäß RillBAK 2008 3,5 - 4,5 313 - 395 F, G, H J or K Zielbereich gemäß RillBAK 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 83,7 - 72,5 8,49 - 9,57
	Na K iCa PH PCO <sub>2</sub> PO <sub>2</sub> Glucose/Glu	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa mm Hg kPa mg/dL g/L mmol/L	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42           2.3         3	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0 33-51 0.33-0.51 1.8-2.8	Osatinha/Crea E03+, 6+, E04+, E3 Na K C pH	unol/L + & G mmol/L,mEq/L mmol/L,mEq/L mm/Hg kPa mg/dL	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,959 68,1 5,08 40	Zielbereich gemäß RIIBAX 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß RIIBAX 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 83,7 - 72,5 8,49 - 9,67 36 - 44
	Na K iCa pH PCO <sub>2</sub> PO <sub>2</sub>	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa mm Hg kPa mm Hg g/L	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0 33-51 0.33-0.51	Osatinha/Crea E03+, 6+, E04+, E3 Na K C D PH P CO <sub>2</sub>	unoilL mmoilL,mEq/L mmoilL,mEq/L mmoilL, mEq/L mmi/Hg kPa mg/dL glL	X (Mean) 4,0 254 LOT 25 (Mean) 120 2,8 79 6,999 68,1 9,08 40 0,40	Zielbereich gemäß RIIBAX 2008 3,5 - 4,5 313 - 395 F, G, H J or K Zielbereich gemäß RIIBAX 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 63,7 - 72,5 8,49 - 9,67 36 - 44 0,36 - 0,44
	Na K iCa PH PCO <sub>2</sub> PO <sub>2</sub> Glucose/Glu	s mmol/L, mEq/L mmol/L, mEq/L mg/dL mg/dL mEq/L mm Hg kPa mm Hg kPa mg/dL g/L mmol/L mg/dL	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42           2.3         3.9	R (Range)         117-126         2.6-3.2         1.33-1.54         5.3-6.2         2.7-3.1         6.987-7.087         51.2-66.2         6.82-8.82         75-105         10.0-14.0         33-51         0.33-0.51         1.8-2.8         3.1-4.7	Osatinita/Crea E03+, 6+, E04+, E3 Na K O PH PCO <sub>2</sub> Glucose/Git	unoilL + & G mmoilL,mEq/L mmoilL,mEq/L mmoilL,mEq/L kPa mg/dL gL mmoilL	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,989 68,1 9,08 40 0,40 2,2	Zielbereich gemäß RiilBAX 2008 3,5 - 4,5 313 - 395 F, G, H, J or K Zielbereich gemäß RiilBAX 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 63,7 - 72,5 8,49 - 9,67 36 - 44 0,36 - 0,44 2,0 - 2,4
	Na K iCa PH PCO <sub>2</sub> PO <sub>2</sub> Glucose/Glu	mmol/L, mEq/L mmol/L, mEq/L mmol/L mg/dL mEq/L mm Hg kPa mm Hg kPa mg/dL g/L mmol/L	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42           2.3         3.9	R (Range) 117-126 2.6-3.2 1.33-1.54 5.3-6.2 2.7-3.1 6.987-7.087 51.2-66.2 6.82-8.82 75-105 10.0-14.0 33-51 0.33-0.51 1.8-2.8	Osatinha/Crea E03+, 6+, E04+, E3 Na K C PH P CO <sub>2</sub> Glucosa/G s BUN	unol/L + & G mmol/L,mEq/L mmol/L,mEq/L mmol/L, mEq/L kPa mg/dL gL mmol/L mg/dL	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 8,989 68,1 9,08 40 0,40 2,2 65	Zelbereich gemäß RiilBAK 2008 3,5 - 4,5 313 - 395 F, G, H, J or K Zelbereich gemäß RiilBAK 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 83,7 - 72,5 8,49 - 9,67 38 - 44 0,36 - 0,44 2,0 - 2,4 56 - 73
	Na K iCa PH PCO <sub>2</sub> PO <sub>2</sub> Glucose/Glu	s mmol/L, mEq/L mmol/L, mEq/L mg/dL mg/dL mEq/L mm Hg kPa mm Hg kPa mg/dL g/L mmol/L mg/dL	R         (Mean)           121         2.9           1.43         5.7           2.9         7.037           58.7         7.82           90         12.0           42         0.42           2.3         3.9	R (Range)         117-126         2.6-3.2         1.33-1.54         5.3-6.2         2.7-3.1         6.987-7.087         51.2-66.2         6.82-8.82         75-105         10.0-14.0         33-51         0.33-0.51         1.8-2.8         3.1-4.7	Otsatinite/Crea E03+, 6+, E04+, E3 Na K O PH P CO <sub>2</sub> Glucose/Git	unoilL + & G mmoilL,mEq/L mmoilL,mEq/L mmoilL,mEq/L kPa mg/dL gL mmoilL	X (Mean) 4,0 354 LOT X (Mean) 120 2,8 79 6,989 68,1 9,08 40 0,40 2,2	Zielbereich gemäß RiilBAK 2008 3,5 - 4,5 313 - 395 F, G, H,J or K Zielbereich gemäß RiilBAK 2008 116 - 124 2,7 - 2,9 75 - 83 6,961 - 7,017 63,7 - 72,5 8,49 - 9,67 36 - 44 0,36 - 0,44 2,0 - 2,4

i-STAT<sup>®</sup> Level 1 Control

LOT 101032 Exp.: 2013-08 Barcode von

Ampalle

27.11.2012

1,39 RIJBÅK 2008 (STAT Qualitate-Daterblatter:

copyright: www.wa-labor.de

- The definition of connectivity is the ability to reliably transfer test information between a point-of-care testing device and an information system.
   Connectivity means no manual transcription in order to move test data into the LIS. Labs need point-ofcare devices that capture all of the necessary information accurately and effectively.
- So, connectivity is the best solution for POCT quality assurance.